http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#Head http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#assertion http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#provenance http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#pubinfo http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#assertion http://purl.obolibrary.org/obo/DOID_0050425 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_0050425 http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00268 http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#association http://www.w3.org/2000/01/rdf-schema#label parkinson s disease ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson s disease the effectiveness of ropinirole hydrochloride tablets were demonstrated in randomized controlled trials in patients with early parkinson s disease who were not receiving concomitant l dopa therapy as well as in patients with advanced disease on concomitant l dopa see clinical pharmacology clinical trials restless legs syndrome ropinirole hydrochloride tablets are indicated for the treatment of moderate to severe primary restless legs syndrome rls key diagnostic criteria for rls are an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations symptoms begin or worsen during periods of rest or inactivity such as lying or sitting symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues and symptoms are worse or occur only in the evening or night difficulty falling asleep may frequently be associated with moderate to severe rls http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00268 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#provenance http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#pubinfo http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#sig http://purl.org/nanopub/x/hasSignature QR1TqOtEinpqsGQtzfMgPsxoamN8mg48F6beuhsN9TqaBs1eUynUTEGBDoxbKvwRbvBu+R2jpiaOu8RtIPUmr4DK3fYgwJr/G7LRSVHBinatt/mxyYJHDChKimCF7UJTSHdWRreOG63vNnnWTNyS9lVOX3pcXQ13KmFldfk1dqE= http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA http://purl.org/dc/terms/created 2021-07-03T12:51:58.740+02:00 http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAVlsOyq5efrKQJcgiZxku4ORrt3DguQIk1wMXvmITfTA https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs